Warning: Your current browser has not been tested extensively with this website, which may result in some some errors with functionality. The following browsers are fully supported:
Please use a different browser.
Figure D19: Disease Resistance in Animal Studies (PFOA and PFOS)
Disease Resistance Assays (PFOA and PFOS):
PFOA:
PFOA:
- No experimental mammalian PFOA data reported.
- Smits (2013) data [green text] from quail.
- Note: Kannan (2006) report sea otters with clinical signs of disease had higher PFOA concentrations in liver (different type of analysis so not included on this graph).
- Note: Kannan (2010) report PFOA concentrations in liver did not differ between populations of bats with white-nose syndrome and healthy reference populations (different type of analysis so not included on this graph).
- Guruge 2009 reported PFOS-associated decreases in disease resistance to influenza A
- There was no significant difference between groups in survival time
- There was a significant, dose-dependent increase in mortality (p=0.014)
- There high dose (0.025mg/kg/bw-day) had a significantly decreased survival rate (p=0.035)
- Body weight was significantly decreased on day 30 in both PFOS treatment groups (p<0.05)
- Note: Kannan (2006) report sea otters with clinical signs of disease had higher PFOS concentrations in liver (different type of analysis so not included on this graph).
- Note: Kannan (2010) report PFOS concentrations in liver did not differ between populations of bats with white-nose syndrome and healthy reference populations (different type of analysis so not included on this graph).
- Black Line separates PFOA data from PFOS